

Wednesday, 06 September 2017

14th International Conference on Thalassaemia & Haemoglobinopathies

17 – 19 November 2017

Thessaloniki, Greece

Friday 17th November 2017 // **Hall TBC**

OPENING CEREMONY

Master of Ceremonies:

- 18.00 – 19.00 Opening remarks
19.00 – 19.15 TIF Award Ceremony

KEYNOTE PRESENTATIONS

Chairpersons: C. Kattamis & D. Loukopoulos

- 19.15 – 19.30 Haemoglobinopathies Care & Cure: Have we reached the end?
19.30 – 19.45 Migration: The aftershocks to the provision of healthcare
19.45 – 20.00 Patients' as Equal Partners in Decision-Making: The Global Reality

Saturday 18th November 2017 // **Olympia B Hall**

08.45 – 10.15 **Session 1: Diagnosis & Prevention**

Chairpersons:

- 08.45 – 09.00 Diagnosis of Haemoglobinopathies: New scientific advances
09.00 - 09.15 New Challenges in diagnosis of haemoglobinopathies: Migration of Populations
09.15 – 09.30 Global Overview of Neonatal Screening Practices of Haemoglobinopathies
09.30 – 09.45 Informed choice in a multicultural world

09.45 – 10.00 Diagnostic strategies on hemoglobinopathy testing, the role of a reference laboratory in the USA

10.00 – 10.15 Discussion

10.15 – 11.30 Session 2: Cornerstones of Clinical Management of Haemoglobinopathies

Chairpersons:

10.15 – 10.30 Optimal Blood Transfusion Therapy in Haemoglobinopathies

10.30 – 10.45 Iron Overload & Chelation in Haemoglobinopathies

10.45 – 11.00 Multidisciplinary Care: the UK Experience

11.00 – 11.15 Best practices in assessing iron overload today: A need for Guidelines?

11.15 – 11.30 Discussion

11.30 – 13.00 Session 3: Managing Complications in Haemoglobin Disorders – New Advances (I)

Chairpersons:

11.30 – 11.50 Endocrine complications

11.50 – 12.10 Cardiac complications

12.10 – 12.30 Liver complications

12.30 – 12.50 Renal complications

12.50 – 13.00 Discussion

13.00 – 14.00 Session 4: Haemoglobinopathies in Focus: Sickle Cell Disease

Chairpersons:

13.00 – 13.15 Clinical Management of Sickle Cell Disease in Childhood & Adolescence

13.15 – 13.30 Clinical Management of Sickle Cell Disease in Adulthood

13.30 – 13.50 *Topic to be Confirmed*

13.50 – 14.00 Discussion

14.00 – 15.30 SATELLITE SESSION 1 – Supported by Novartis

15.30 – 16.30 Session 5: Challenges in Delivering Treatment

Chairpersons:

15.30 – 15.45 National policies in ensuring access to quality & safety of drugs: A challenge or a prerequisite

- 15.45 – 16.15 Adherence to Treatment: Doctor vs Patient Perspective
- 16.15 – 16.30 Patient care: Unmet needs globally
- 16.30 – 17.30 Session 6: Improving quality healthcare – Networks & Accreditation**
Panellists:
- 16.30 – 16.45 The EUROBLOODNET Experience
- 16.45 – 17.00 Global initiatives for improving quality healthcare by the Thalassaemia International Federatio
- 17.00 – 17.30 Panel Discussion – Challenges in securing quality healthcare services for haemoglobinopathy patients
- 17.30 – 19.00 SATELLITE SESSION 2 – Supported by Cerus**

Sunday 19th November 2017

08.30 – 09.30

Oral Presentations

Hall 1 – Olympia B

Hall 2 – V. Patoulidou

Hall 3 – Ilida

Hall 3 – Kallipateira

Topics to be announced

Topics to be announced

Topics to be announced

Topics to be announced

Plenary Sessions: Olympia B Hall

09.30 – 10.30

Session 7: Managing Complications in Haemoglobin Disorders – New Advances (II)

Chairpersons:

09.30 – 09.50

Osteoporosis

09.50 – 10.10

Pain: Time for more action?

10.10 – 10.20

The role of CNS in the care of haemoglobinopathy patients

10.20 – 10.30

Discussion

10.30 – 11.15

Session 8: Quality of Life in Patients with Haemoglobin Disorders

Chairpersons:

10.30 – 10.40

Quality of Life: Transfusion Dependent Thalassaemia vs Non-Transfusion Dependent

Page 3 of 4

Coffee & Lunch will be available in Healthcare Professionals Exhibition Area (Olympia C) at designated times on 18 & 19 November 2017.

	Thalassaemia
10.40 – 10.50	Moving towards Patient Reported Outcomes
10.50 – 11.00	Quality of Life – Patient Individual Medical Consultant Perspective
11.00 – 11.15	Discussion
11.15 – 13.00	Session 9: New Advances in Haemoglobinopathies Chairpersons:
11.15 – 11.45	The changing face of Management: Latest update of on-going clinical trials
11.45 – 12.00	Advances in Gene Therapy Trials
12.00 – 12.15	HCV Treatment Advances for Thalassaemia Patients – <i>G. Papatheodorides</i>
12.15 – 12.30	Gene Editing
12.30 – 13.00	Discussion
13.00 – 13.15	Closing remarks
13.15 – 14.00	LUNCH

DRAFT